Get started
Author

Dianne Nguyen

Budget Impact Analysis of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) for Recurrent Clostridioides difficile Infection in the United States
2025 · Michele Wilson, Yoav Golan, et al. · Infectious Diseases and Therapy · 7
PDF
Self-appraisal of body appreciation and health identity among adults with Osteogenesis Imperfecta
2026 · Shae-Marie R. Stafford-Trujillo, Ryan J. McCarty, et al. · Psychology Health & Medicine
Self-perceived burden and mental health outcomes in adults with osteogenesis imperfecta
2026 · Emily R. Strouphauer, Camille Villar, et al. · Journal of Health Psychology
Sal329 COMPARATIVE EFFECTIVENESS OF VOWST VS. VANCOMYCIN AND FIDAXOMICIN FOR THE PREVENTION OF RECURRENT C. DIFFICILE INFECTION IN REAL-WORLD PRACTICE
2026 · Paul Feuerstadt, Karen Peralta Martinez, et al. · Gastrointestinal Endoscopy
Sal329 COMPARATIVE EFFECTIVENESS OF VOWST VS. VANCOMYCIN AND FIDAXOMICIN FOR THE PREVENTION OF RECURRENT C. DIFFICILE INFECTION IN REAL-WORLD PRACTICE
2026 · Paul Feuerstadt, Karen Peralta Martinez, et al. · Gastroenterology
Correction: Budget Impact Analysis of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) for Recurrent Clostridioides difficile Infection in the United States
2025 · Michele Wilson, Yoav Golan, et al. · Infectious Diseases and Therapy
PDF
S2130 Comparison of the Efficacy and Safety of Live Fecal Microbiota Therapeutics for Recurrent Clostridioides difficile Infection (CDI): Matching-Adjusted Indirect Treatment Comparison in Patients With ≥1 CDI Recurrence
2025 · Conor McCloskey, Corinne Le Reun, et al. · The American Journal of Gastroenterology
Response to “Fulminant Clostridioides difficile Infection Following Fecal Microbiota Spores Compared to Fecal Microbiota Transplant”
2025 · Jason Goldsmith, Dianne Nguyen, et al. · Clinical Gastroenterology and Hepatology
PDF
Sa1943: FECAL MICROBIOTA SPORES, LIVE-BRPK (FORMERLY SER-109) IN ADULTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION IN THE UNITED STATES: ANALYSIS OF SINGLE OR REPEAT USE IN ROUTINE CLINICAL SETTINGS
2025 · Ashish Gumaste, Michael Chen, et al. · Gastroenterology
S282 Real-World Use of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) in Adults With Recurrent Clostridioides difficile Infection in the United States
2024 · Stuart Akerman, Ashish Gumaste, et al. · The American Journal of Gastroenterology
S334 Systematic Literature Review and Meta-Analysis of Live Fecal Microbiota Therapeutics for Recurrent Clostridioides Difficile Infection
2024 · Conor McCloskey, Corinne Le Reun, et al. · The American Journal of Gastroenterology
S280 Safety of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) in Participants With Recurrent Clostridioides difficile Infection and Comorbidities: Findings From an Integrated Analysis of Phase 3 Trials
2024 · Matthew Sims, Charles S. Berenson, et al. · The American Journal of Gastroenterology
Sa1911 CLINICAL AND ECONOMIC OUTCOMES OF MICROBIOME THERAPY FOR PREVENTING RECURRENCE IN RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION (CDI) IN THE US: COMPARISON OF FECAL MICROBIOTA SPORES, LIVE-BRPK (FORMERLY SER-109) VS FECAL MICROBIOTA, LIVE-JSLM
2024 · Yoav Golan, Alpesh Amin, et al. · Gastroenterology
Works count: 13
Citation count: 7
H-index: 1
I10-index:
Year
Topic
Type